CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial

Official title:

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01664910
• Other study ID #: 2012-0265
• Secondary ID: NCI-2012-0207220
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 29, 2012
• Est. completion date: June 28, 2023

Study information

• Verified date: July 2023
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and the best dose of inotuzumab ozogamicin when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab before donor stem cell transplant in treating patients with lymphoid malignancies. Giving chemotherapy drugs, such as fludarabine phosphate and bendamustine hydrochloride, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cell and helps stop the patient's immune system from rejecting the donor's stem cells. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cell from a donor can make an immune system response against the body's normal cells. Giving fludarabine phosphate and bendamustine hydrochloride before the transplant together with anti-thymocyte globulin and tacrolimus may stop this from happening.

Description:

PRIMARY OBJECTIVES: I. To characterize the safety of anti-cluster of differentiation (CD) 22 immunoconjugate inotuzumab ozogamicin (CMC-544), when administered in conjunction with fludarabine (fludarabine phosphate), bendamustine (bendamustine hydrochloride), and rituximab as non-myeloablative preparative regimen for allogeneic stem cell transplantation for CD22-positive lymphoid malignancies. SECONDARY OBJECTIVES: I. To estimate tumor response. II. To determine overall and event-free survival rates by histology subtype. OUTLINE: This is a dose-escalation study of inotuzumab ozogamicin. Patients receive inotuzumab ozogamicin intravenously (IV) over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with matched unrelated donors (MUD) receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or orally (PO) daily beginning on days -2 to 180 followed by taper in the absence of graft-versus-host disease (GVHD) and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic bone marrow (BM) or peripheral blood stem cell (PBSC) transplant on day 0. After completion of study treatment, patients are followed up periodically.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: June 28, 2023
• Est. primary completion date: June 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with B-cell hematological malignancies who are eligible for allogeneic transplantation
• Patients must have a fully-matched sibling donor or a matched unrelated donor identified
• Performance score of at least 80% by Karnofsky or 0 to 2 Eastern Cooperative Oncology Group (ECOG)
• Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrhythmias or symptomatic heart disease
• Forced expiratory volume in one second (FEV1) >= 50%
• Forced vital capacity (FVC) >= 50%
• Corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 50%
• Serum creatinine < 1.6 mg/dL
• Serum bilirubin < 2 mg/dL upper limit of normal (unless due to Gilbert's disease; patient with this disease should have a right upper quadrant ultrasound evaluation before treatment)
• Serum glutamate pyruvate transaminase (SGPT) < 2 x upper limit of normal
• Men and women of reproductive potential must agree to follow accepted birth control methods (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study
• Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding; pregnancy testing is not required for post-menopausal or surgically sterilized women

Exclusion Criteria:

• Patient with active central nervous system (CNS) involvement
• Known infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV)-I, hepatitis B, or hepatitis C
• Patients with other malignancies diagnosed within 2 years prior to study registration; skin squamous or basal cell carcinoma are exceptions
• Active bacterial, viral or fungal infections
• History of stroke within 6 months
• History of biliary colic attack
• A prior autologous transplant within 3 months of study entry or allogeneic stem cell transplant
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• Patient has received other investigational drugs within 3 weeks before study registration
• Serious nonmalignant disease which, in the opinion of the investigator would compromise protocol objectives
• Prior exposure to CMC-544 within past 6 months
• Established refractoriness to CMC-544

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Hematopoietic and Lymphoid Cell Neoplasm

Intervention

Procedure:
• Allogeneic Bone Marrow Transplantation
Undergo allogeneic BM transplant
• Allogeneic Hematopoietic Stem Cell Transplantation
Undergo allogeneic PBSC or BM transplant

Biological:
• Anti-Thymocyte Globulin
Given IV

Drug:
• Bendamustine Hydrochloride
Given IV
• Fludarabine Phosphate
Given IV

Biological:
• Inotuzumab Ozogamicin
Given IV

Drug:
• Methotrexate
Given IV

Procedure:
• Peripheral Blood Stem Cell Transplantation
Undergo allogeneic PBSC transplant

Biological:
• Rituximab
Given IV

Drug:
• Tacrolimus
Given IV or PO

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum-tolerated dose (MTD) of inotuzumab ozogamicin	Defined as the highest dose for which the probability of toxicity is closest to 30%.	Up to 30 days
Primary	Incidence of dose-limiting toxicity	Defined as grade III or IV renal, hepatic, intestinal, neurologic, pulmonary or cardiac adverse events, as well as graft failure or death at any time.	Up to 30 days
Secondary	Objective overall response (complete remission and partial remission)	Estimated with a 95% confidence interval in the dose that is declared the MTD. Logistic regression will be used to assess the association between response and disease and clinical characteristics of interest.	Up to 3 years
Secondary	Overall survival (OS)	Kaplan-Meier survival curves will be used to estimate OS. Cox proportional hazards regression methodology will be used to assess the association between disease and clinical characteristics and the survival outcomes.	Up to 3 years
Secondary	Recurrence-free survival	Kaplan-Meier survival curves will be used to estimate recurrence-free survival. Cox proportional hazards regression methodology will be used to assess the association between disease and clinical characteristics and the survival outcomes.	Up to 3 years
Secondary	Cumulative incidence of acute and chronic graft versus host disease (GVHD)	The method of Gooley et al will be used to estimate the cumulative incidence of acute and chronic GVHD.	Up to 3 years

External Links

•   University of Texas MD Anderson Cancer Center Website